Circulating Cell-Free SHOX2 DNA Methylation Is a Predictive, Prognostic, and Monitoring Biomarker in Adjuvant and Palliative Anti-PD-1-Treated Melanoma

Simon Fietz,Eric Diekmann,Luka de Vos,Romina Zarbl,Alina Hunecke,Ann-Kathrin Glosch,Moritz Färber,Judith Sirokay,Friederike Hoffmann,Anne Fröhlich,Alina Franzen,Sebastian Strieth,Jennifer Landsberg,Dimo Dietrich
DOI: https://doi.org/10.1093/clinchem/hvad230
IF: 12.114
2024-02-01
Clinical Chemistry
Abstract:Abstract Background The majority of metastatic melanoma patients initially do not respond or acquire resistance to anti-programmed cell death 1 (PD-1) immunotherapy. Liquid biopsy biomarkers might provide useful early response information and allow for personalized treatment decisions. Methods We prospectively assessed circulating cell-free SHOX2 DNA methylation (SHOX2 ccfDNAm) levels and their dynamic changes in blood plasma of melanoma patients by quantitative methylation-specific polymerase chain reaction. Patients were treated with either palliative (n = 42) or adjuvant (n = 55) anti-PD-1 immunotherapy. Moreover, we included n = 126 control patients without evidence of malignant disease. We analyzed SHOX2 ccfDNAm status prior to and 4 weeks after palliative treatment initiation with regard to outcome [objective response, progression-free survival (PFS), and overall survival (OS)]. In the adjuvant setting, we associated longitudinal SHOX2 ccfDNAm status with disease recurrence. Results Sensitivity was 60% with 25/42 melanoma patients showing increased SHOX2 ccfDNAm levels, whereas specificity was 98% with 123/126 (P < 0.001) control patients having SHOX2 ccfDNAm levels below cut-off. Pretreatment SHOX2 ccfDNAm status did not correlate with outcome; however, SHOX2 ccfDNAm negativity 4 weeks after palliative treatment initiation was strongly associated with improved survival [PFS: hazard ratio (HR) = 0.25, P = 0.002; OS: HR = 0.12, P = 0.007]. Pretreatment positive patients who reached SHOX2 ccfDNAm clearance after 4 weeks of immunotherapy showed an exceptionally beneficial outcome. SHOX2 ccfDNAm testing allowed for an early detection of distant metastases in adjuvant-treated melanoma patients. Conclusions Our study suggests SHOX2 ccfDNAm to be an early predictor of outcome in anti-PD-1 treated melanoma patients. SHOX2 ccfDNAm testing may aid individualized treatment decision-making.
medical laboratory technology
What problem does this paper attempt to address?
The paper primarily explores the value of circulating cell-free SHOX2 DNA methylation (SHOX2 ccfDNAm) as a predictive, prognostic, and monitoring biomarker for melanoma patients undergoing anti-PD-1 immunotherapy. ### Research Background and Objectives - **Background**: Most metastatic melanoma patients either do not initially respond to PD-1 immunotherapy or gradually develop resistance. Liquid biopsy biomarkers may provide early response information and allow for personalized treatment decisions. - **Objective**: To evaluate the levels and dynamic changes of circulating cell-free SHOX2 DNA methylation in the plasma of melanoma patients receiving adjuvant or palliative anti-PD-1 immunotherapy. The study aims to determine whether SHOX2 ccfDNAm can serve as an early predictive indicator and assist in making individualized treatment decisions. ### Main Findings - **Sensitivity and Specificity**: In the study, 60% of melanoma patients (25 out of 42 cases) showed elevated levels of SHOX2 ccfDNAm, while 98% (123 out of 126 cases) of the control group (patients with no evidence of malignant disease) had SHOX2 ccfDNAm levels below the threshold. - **Prognostic Relevance**: Pre-treatment SHOX2 ccfDNAm status was not associated with outcomes; however, patients who were SHOX2 ccfDNAm negative 4 weeks after starting palliative treatment were significantly associated with better survival rates. - **Treatment Response and SHOX2 ccfDNAm**: Patients who were SHOX2 ccfDNAm positive before treatment and achieved SHOX2 ccfDNAm clearance 4 weeks after immunotherapy showed particularly beneficial outcomes. - **Recurrence Detection**: SHOX2 ccfDNAm testing allowed for early detection of distant metastasis in melanoma patients receiving adjuvant anti-PD-1 therapy. ### Conclusion - The study suggests that SHOX2 ccfDNAm may be a marker for early prediction of outcomes in melanoma patients undergoing anti-PD-1 therapy. - SHOX2 ccfDNAm testing may aid in making individualized treatment decisions.